Zacks Investment Research
02 Oct 2026, 23:15 UTC · 1h ago
Impact · against what's priced in
PACB is facing a negative outlook as upcoming quarterly EPS and revenue are both projected to decline year-over-year. Despite a massive recent rally in share price, the fundamental projections suggest the stock may be overextended heading into its earnings report.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Pacific Biosciences of California's upcoming quarterly EPS is projected at -$0.13, an 8.33% decrease from the same quarter last year.
Priced inconsensus estimate
So whatA miss on this already declining EPS trend could lead to a downward revision of the full-year -$0.43 per share projection.
More negative than 77% of claims this week
Consensus revenue estimates for the upcoming quarter are $37.86 million, representing a 1.51% decline year-over-year.
Continue reading
5 related stories
The stock's 93% one-month rally contrasts sharply with projected quarterly revenue of $37.86 million and EPS of -$0.13, both of which represent year-over-year declines.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inconsensus estimate
So whatWith full-year revenue projected at $156.1 million, the company needs to average ~$39 million per quarter to meet targets.
More negative than 70% of claims this week
PACB shares have increased 93.08% over the last month, significantly outperforming the Medical sector's 3.74% loss.
Priced inhistorical price data over last month
So whatSuch a rapid ascent suggests the stock is highly volatile and potentially overextended heading into the next earnings print.
More positive than 45% of claims this week
Which stocks this story touches
More negative than 67% of ticker scores this week
Despite recent price gains, the company has a Zacks Rank of #4 (Sell) and projected declines in EPS and revenue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
—
PACB hasn't traded since this ran. Last close $2.54 (Oct 2); the reaction starts at the next open.
PACB chart →
